Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wook Just think how fast those shares will be scarfed up on SUNRISE approval.
Yes it went up a bit from earlier in week. Good.
Correct, valuation is developing on many fronts. SUNRISE approval will set up leverage.
bio It is all about the leverage. PPHM is developing nicely on valuation.
Hutschi Any more thoughts on this POST:
May 20 (Reuters) - U.S. healthcare conglomerate Johnson & Johnson <JNJ.N> said on Wednesday it expects to submit more than 10 new medicines with annual revenue potential of at least $1 billion each to regulators by 2019, and is testing dozens of new uses for existing medicines.
J&J said it would file for approval of daratumumab for the blood cancer multiple myeloma in the United States and Europe this year based on mid-stage clinical data.
Wells Fargo analyst Larry Biegelsen forecast daratumumab sales reaching $1.3 billion by 2019.
The company is looking to bounce back from previous failure in Alzheimer's disease with multiple programs, including an early-stage drug it believes has the potential to prevent amyloid plaque buildup in the brain and another that aims to clear it.
Pharmaceuticals has been a bright spot for the company at a time when its medical devices and consumer products have seen sharp declines, hurt by competition and the strong dollar.
During a pharmaceutical pipeline review for analysts and investors, J&J outlined an ambitious portfolio of drugs in development aimed at sustaining above-industry compound annual growth through 2019. The industry rate over that period is expected to be about 3 percent.
The review comes as the industry prepares for the introduction of copycat versions of expensive biologic drugs, such as J&J's rheumatoid arthritis (RA) treatment Remicade, which has annual U.S. sales of more than $4 billion and a patent that expires in 2018.
J&J's worldwide pharmaceuticals head Joaquin Duato said he believes Remicade's established safety would be an advantage over eventual biosimilar newcomers.
"Biosimilars are not generics and we expect the market to behave quite differently," Duato said.
Still, the company highlighted a new antibody for RA being developed with GlaxoSmithKline <GSK.L>, and one for psoriasis that it touted as more effective that Abbott's <ABT.N> big-selling Humira.
The company is targeting Crohn's disease with a new drug being developed along with a companion diagnostic aimed at identifying patients likely to have the best response, and is beginning Phase III trials of a promising drug for treatment resistant depression.
J&J is jumping on the immuno-oncology bandwagon with programs for lung, prostate and blood cancers aimed at harnessing the immune system to attack tumors.
It also aims to become a major player in the hepatitis C market now dominated by Gilead Sciences <GILD.O> through a deal announced Tuesday with Achillion Pharmaceuticals <ACHN.O>.
Investors, however, appear underwhelmed. J&J shares slipped 0.3 percent to $103.65.
Yes sir u bet 1st lookin PR is a milestone for SUNRISE and a buying point at the very least for retail.
It will trade differently as we near the approval point. In the mean time it gives anyone interested a low entry point to establish a position.
Couch My son bought 13000 @1.24. Good entry for him.
Jim In my view SUNRISE will be approved. Good science. Just need to wait for results. I am thinking within 6-8 months the PPS will reflect this sentiment. Could start movement upward late August early September.
Frivolous lawsuits in vogue where money can be had.
Endo
ITSABOUTTIME
Here are my numbers, adding a few known holdings.
me 126,000
son 13,000
brother-in law 100,000
co-worker (verified on screen) 44,000
Total 283,000
Plus several friends not sure what they own.
Time for the lawyers to earn some more doe.
Yes it is in material. March on to Bavi approval.
Jim Finger is on the trigger just need stamp of approval.
Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) has witnessed a drop of 0.6% or 50,844 shares in its short figure. The short interest diminution took it from 8,548,124 on June 30,2015 to 8,497,280 on July 15,2015. In terms of floated shares, the short interest was calculated to be 4.3%. The days to cover are 9 given that the daily volume averaged 909,340 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on July 24th .
That would work I do believe.
Arthur D. Levinson (born March 31, 1950) is an American businessman and is the current CEO of Calico (a Google venture) and chairman of Apple Inc. (2011 to present). He is the former chairman of Genentech (1999 to 2014) and former chief executive officer of Genentech (1995–2009).
In addition to serving on the board of Apple. Inc. (2000–present), Levinson serves on the board of directors of the Broad Institute (affiliated with MIT and Harvard).[2] Previously, Levinson had served on the board of directors at F. Hoffmann-La Roche (2010-2014), NGM Biopharmaceuticals (2009-2014), and Amyris Biotechnologies (2009-2014). He currently serves on the Board of Scientific Consultants of the Memorial Sloan Kettering Cancer Center, the Industrial Advisory Board of the California Institute for Quantitative Biosciences (QB3), the Advisory Council for the Princeton University Department of Molecular Biology and the Advisory Council for the Lewis-Sigler Institute for Integrative Genomics.[3]
RCJ Don't get me wrong I would love to be wrong on this one assuming positive outcome. If so, I will stop putting bird seed in my bird feeder.
RCJ
Who knows, I'll take a whack at it, to float an agenda? Perhaps to create confusion, insecurity. The list goes on. Nothing new, I seen this movie many times over the years.
Well the little birdie landed on my shoulder and told me SK is scheduled to be out on vacation this Friday.
Will see who is right the little birdie or the leaker.
What else?
Probably scheduled to be out on vacation by Friday
SUNRISE approval is key. These lawsuits will diminish in time.
so full circle back to: does pphm have the chops for this?
CP
I am going out on a limb here. Will see for sure but I think the numbers will come in much higher around 13 to 15 months. Based on ECOG and larger trial etc.
The 7.5 months is about 50% increase on the 5.4 months of the PII Ctrl arm results. The 1 and 3 mg/Kg Bavituximab arm had about 11 and 13 months (hence those 12 months golfho used in his simulations). This data comes from PPHM but I don't remember of it was a PR or a Q&A on a CC. PPHM expressed it in % improvement on Docetaxel alone. So it depends a little of what you use as the basis. 3.8, 5.6, et.
Sunstar I think you have it covered pretty well with few variences.
GEO That's good. Nice to know. EOM
Carboat In a balanced portfolio where the eggs go into several baskets does not constitute a dangerous investment strategy. I do not invest in blind faith. In the speculative basket I focus on the direction of the companies based on several factors staying focused on where the companies are heading verses where they were or how they got there. What you describe below is part of that growing pain. I have made my millions sifting through all of these factors then establishing a position based on price and timing. I have traded in and out of this stock through the years but established an investment position in 2013. In my opinion this will be a $50 stock at minimum in the years to come.
However I do agree with you that without spreading your risk it makes for some white knukle moments.
Blind faith is a dangerous investment strategy. To conclude there is little to no risk here makes little sense given: company history, bod make-up, lack of institutional interest, lack of insider buy interest, past failed trials, lack of any investor relations response and $1.25 a share.
Geo If you believe in what your invested in then the PPS being at the lower end of yearly chart is an opportunity to add more shares to your position if you so choose. I think few here are in any sort of panic mode and are dumping shares due to the PPS. In fact it is obvious most here are optimistic but frustrated with the timeline to get Bavi approved for commercialization and the PPS is a reminder of it not being approved yet.
MD you know PPHM has the goods with BAVI were fighting time now for thumps up.
LOL Hopefully you'll be able to fill that barrel with cold hard cash
after FDA approval granted.
Bio you nailed all the points of contention. Glad you looked them up. Remembered them in the CC and ASM. Thanks.
Agreed EOM
Stevedazs That's ok. Hope the PPS reaches over $25 in due time should help you. GLTU
CP my cluster (family & close friends) have actually increased their holdings due to the drop in PPS. Just remembered my coworker picked up 44,000 this past week @1.26 & 1.27.
I expect FDA approval-now that is exciting!
Well stated I agree- my family members hold approximately 239,000
two close friends another 144,000. There's 383,000 right there alone.
Perfectly stated. GLTA EOM
goat no doubt EOM
GEO I agree with your sentiment. I expect volume will be over 40 MIL when FDA approval announced.
Were closing in on the first look-in. Sept. 1st looks good for it.
Endo I bought in just two weeks before that run. I bailed in the $7 range though and was surprised to see it continue to rise.
I think will double 60% and the Loofman rocket will blast off. Loof will be chugging down a cold one while waving to all of the short folks below on the way up into the stratosphere.